Skip to main content
CRVO
NASDAQ Life Sciences

New Neflamapimod Data Reinforce Positive Effects in DLB, Bolstering Phase 3 Strategy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.62
Mkt Cap
$39.257M
52W Low
$3.58
52W High
$16.94
52W Position info
29% above low
Off High info
73% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CRVO sits 29% above its 52-week low of $3.58.

Summary

CervoMed announced new analyses from its Phase 2b RewinD-LB clinical trial for neflamapimod at the AD/PD™ 2026 Conference. The data reinforce positive effects in Dementia with Lewy Bodies (DLB) patients without Alzheimer's disease co-pathology, showing greater clinical benefit in these specific subgroups. This news builds on the company's recent announcement (March 17) of FDA alignment on the design for its planned Phase 3 trial, as these new analyses further validate the patient enrichment strategy and dosing regimen for that crucial upcoming trial. For a company facing significant financial challenges, including a going concern warning and a critical 6-month cash runway reported in recent SEC filings, this strong clinical data is vital. It significantly de-risks the path to Phase 3 and could be instrumental in attracting necessary financing or partnerships.

At the time of this announcement, CRVO was trading at $4.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $3.58 to $16.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRVO - Latest Insights

CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.48 info
Change: -$0.270 (-15%) info
Market Cap: $21.923M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.48 info
Change: -$1.54 (-51%) info
Market Cap: $21.923M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.48 info
Change: -$1.15 (-44%) info
Market Cap: $21.923M info
CRVO
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.64
Real-time Price: $1.48 info
Change: -$1.15 (-44%) info
Market Cap: $21.923M info
CRVO
Aug 10, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.87
Real-time Price: $1.48 info
Change: -$1.39 (-48%) info
Market Cap: $21.923M info